(AdSS, which adjusts the RTSS for rescue medication use) and daily individual rhinoconjunctivitis symptom scores. The primary efficacy endpoint, the daily CS during the pollen period while on treatment, was analyzed using a repeated measures ANCOVA model, as were the above secondary efficacy endpoints. The safety of the treatment was documented by means of adverse event reporting, laboratory data and physical examination findings. Results: The 300IR group showed a relative improvement in daily CS versus placebo of -28.2% (relative difference in LS Means, 95%, CI [-43.4%; -13.0%], P ¼ 0.0003). Significant improvements in RTSS and AdSS were consistent with previous European studies. There were also significant improvements in the individual symptoms: sneezing, rhinorrhea, nasal congestion, itchy eyes and watery eyes. The 300IR SLIT tablet was generally well tolerated. The most commonly reported treatment-emergent adverse events (TEAEs) in the 300IR group were application site-reactions: oral pruritus, throat irritation, and nasopharyngitis. No drug-related serious TEAEs were reported. The overall safety profile of 300 IR SLIT tablet was consistent with that observed in European studies. Conclusions: The 300IR SLIT tablet showed clinically meaningful efficacy, with significant improvements on the primary and secondary endpoints. The treatment was well-tolerated. Overall, the results in United States are consistent with European observations. Background: Oral and sublingual immunotherapy to food allergens aim to enable the safe consumption of the foods containing these allergens. Methods: Systematic review of intervention studies, searching 11 international databases and contacting an international panel of experts. Studies were critically appraised using the Cochrane approach and meta-analysed. Results: We identified 721 potentially relevant papers, from which we selected 16 reports of 14 eligible trials (12 randomised controlled trials and 2 controlled clinical trials). Eleven of these trials evaluated oral immunotherapy and the remaining 3 investigated sublingual immunotherapy.Meta-analysis revealed that immunotherapy substantially reduced the average risk of persisting food allergy in patients (RR ¼ 0.24; 95% CI, 0.11-0.50). Pooling of the safety data however revealed an increased average risk of systemic adverse reactions in those receiving immunotherapy (RR ¼ 1.13; 95% CI, 1.00-1.27); the average risk of local (minor oropharyngeal/gastro-intestinal) adverse reactions was also increased in those receiving immunotherapy (RR ¼ 1.16; 95% CI, 1.04, 1.30). Meta-analysis of immunological data demonstrated that allergen skin prick test wheal diameter significantly decreased in experimental groups compared to controls (mean difference -2.96 mm; 95% CI, -4.48, -1.45), whilst specific-IgG4 increased by an average of 19.9 mg/ mL (95% CI, 17.1, 22.6); however there was no change in specific IgE: -5.2 kU/L (95% CI, -12.39, 1.99). Conclusions: Oral/sublingual immunotherapy substantially reduces the risk of food allergy, this effect being mediated by immunological mechanisms. However, because of the stringent exclusion criteria used in many of the reviewed studies and the increased risk of systemic adverse events, immunotherapy cannot yet be recommended for routine clinical practice. Future research needs to focus on larger randomised controlled trials investigating long-term clinical tolerance induction, impact on quality of life and estimating the cost-effectiveness of treatment. Overall, this appears to be a promising line of potentially disease-modifying treatment for people with a range of IgE-mediated food allergies. Background: Management of hereditary angioedema (HAE) comprises the prophylaxis and emergency treatment of edematous attacks. Our aim was to appraise the wide variety of the prophylactic use of plasma-derived human C1-inhibitor concentrate in HAE type I and type II patients. Methods: 125 patients with HAE (54 males, 71 females) were included in our study. Classical short-term prophylaxis (STP) was administered before surgical or diagnostic interventions in the head and neck region and other types of major surgery, as well as before endotracheal intubation. Alternatively, STP was introduced before the expected and unavoidable onset of triggering factors.
Background: Oral and sublingual immunotherapy to food allergens aim to enable the safe consumption of the foods containing these allergens. Methods: Systematic review of intervention studies, searching 11 international databases and contacting an international panel of experts. Studies were critically appraised using the Cochrane approach and meta-analysed. Results: We identified 721 potentially relevant papers, from which we selected 16 reports of 14 eligible trials (12 randomised controlled trials and 2 controlled clinical trials). Eleven of these trials evaluated oral immunotherapy and the remaining 3 investigated sublingual immunotherapy.Meta-analysis revealed that immunotherapy substantially reduced the average risk of persisting food allergy in patients (RR ¼ 0.24; 95% CI, 0.11-0.50). Pooling of the safety data however revealed an increased average risk of systemic adverse reactions in those receiving immunotherapy (RR ¼ 1.13; 95% CI, 1.00-1.27); the average risk of local (minor oropharyngeal/gastro-intestinal) adverse reactions was also increased in those receiving immunotherapy (RR ¼ 1.16; 95% CI, 1.04, 1.30). Meta-analysis of immunological data demonstrated that allergen skin prick test wheal diameter significantly decreased in experimental groups compared to controls (mean difference -2.96 mm; 95% CI, -4.48, -1.45), whilst specific-IgG4 increased by an average of 19.9 mg/ mL (95% CI, 17.1, 22.6); however there was no change in specific IgE: -5.2 kU/L (95% CI, -12.39, 1.99). Conclusions: Oral/sublingual immunotherapy substantially reduces the risk of food allergy, this effect being mediated by immunological mechanisms. However, because of the stringent exclusion criteria used in many of the reviewed studies and the increased risk of systemic adverse events, immunotherapy cannot yet be recommended for routine clinical practice. Future research needs to focus on larger randomised controlled trials investigating long-term clinical tolerance induction, impact on quality of life and estimating the cost-effectiveness of treatment. Overall, this appears to be a promising line of potentially disease-modifying treatment for people with a range of IgE-mediated food allergies. Methods: 125 patients with HAE (54 males, 71 females) were included in our study. Classical short-term prophylaxis (STP) was administered before surgical or diagnostic interventions in the head and neck region and other types of major surgery, as well as before endotracheal intubation. Alternatively, STP was introduced before the expected and unavoidable onset of triggering factors. Results: Before diagnosis of HAE, 128 interventions performed on 43 out of 125 patients induced edema: dental procedures (99 interventions in forty patients), ENT interventions (13/9 patients), surgery in the head and neck region (2/2 patients), surgery under general anesthesia (3/3 patients), gastroduodenoscopy (2/2 patients), delivery (6/6 patients) and artificial abortion (3/ 2 patients). After diagnosis of HAE, 500 IU of C1-INH concentrate was administered for STP, one hour before dental intervention (to 14 patients in 26 cases), surgery on the head or neck (to 7 patients in 7 cases), surgery under ETN (to 11 patients in 12 cases), diagnostic procedures (1 colonoscopy, 2 bronchoscopy, 4 gastroduodenoscopy, 1 cardiovascular catheterization), artificial abortion (to 4 patients in 6 cases), or childbirth (to 11 patients in 11 cases). Thirty-three of the 125 patients received prophylactic treatment on 70 occasions altogether. The medical history was positive for oedema provoked by medical interventions in 20 of the 33 patients undergoing STP with C1-INH concentrate. Eight patients received alternative prophylaxis: 2 patients during airway infections, 5 others before stressful life events, and one patient on the first day of the menstrual cycle over 4 months. In all cases, C1-INH concentrate prevented the occurrence of attacks. Conclusions: STP with C1-INH concentrate was effective in preventing angioedematous attacks in all cases. After interventions, during 48 hours observation period, edematous attacks did not occur. Repeated administration did not diminish its efficacy. C1-INH concentrate was well tolerated, and it was never associated with potentially treatment-related adverse effects. We describe 2 patients with AAE who were treated with icatibant during acute attacks. Patient 1 is an 86 year old male who reported cutaneous and abdominal attacks of angioedema beginning 2 years earlier with a frequency of 2 to 3 month. He had low C1-INH (antigenic and functional) C4 levels, normal C1q levels and detectable of anti-C1-INH IgM and anti-C1q IgA. Because of increased frequency, his attacks were treated with icatibant (30 mg s.c.). Patient 2 is a 64 year old female who reported angioedema of the tongue and upper limbs in the last 4 years. Her C4, C1-INH and C1q were low. Monoclonal gammopathy (6%) and IgA anti C1-INH were found. After the diagnosis she started icatibant for acute attacks. Results: The first patient used icatibant consecutively for 20 attacks (mainly abdominal), with rapid resolutions of symptoms and no adverse events. Symptoms resolution began 30 minutes after administration of icatibant and resolution was complete in 3 to 4 hours. The second patient used icatibant for a tongue attack, a mixed cutaneous-tongue attack and a severe facial attack, with first symptom improvement in 25 minutes and complete resolution after 16 to 18 hours. The only adverse event was erythema at the injection site lasting few minutes. Conclusions: Icatibant is an effective and well tolerated treatment of acute attacks in patients with AAE. Our data suggest that blocking bradykinin activity could be considered a good therapeutic strategy particularly in patients with anti-C1-INH antibodies. Methods: Thirty-one patients received 30 mg icatibant subcutaneously at various times for 121 swelling attacks. The time periods between onset of attacks and icatibant injection, icatibant injection and the first symptom relief, and icatibant injection and resolution of symptoms or, in some attacks, the start of a rebound attack were compared in 3 patient groups with different times to injection. Results: Data are reported as mean 6 SD. In 61 attacks treated at 2 or less hours after attack onset, the time to first relief was 1 6 0.9 hours and the time to symptom resolution was 12.9 6 11.5 hours. In 43 attacks treated at more than 2 to 5 hours, the time to first relief was 0.8 6 1.2 hours and the time to resolution was 15.1 6 15.3 hours. In 17 attacks treated later than 5 hours after attack onset, time to first relief was 0.6 6 0.6 hours and time to resolution was 12.6 6 10.3 hours. The percentages of attacks with first symptom relief within 30 minutes in the 3 groups were 59%, 70%, and 64.7%, respectively. There were no statistically significant differences between the groups. In a subgroup of 20 attacks treated within 1 hour after attack onset, the time to first relief was 0.6 6 0.3 hours and the time to symptom resolution was 10 6 12 hours. The only adverse events were injection site reactions that all resolved without intervention. Conclusions: Icatibant is equally effective in early and delayed treatment of acute HAE attacks, with an early onset of relief. Background: Previous studies from our group have demonstrated that IgEmediated basophil activation leads to release of TNFa that in turn can induce matrix metallo-proteinase-9 (MMP-9) release from monocytes. We wished to investigate if serum from chronic spontaneous urticaria-patients with autoantibodies against IgE/IgE-receptor could induce TNFa and MMP-9 release from donor PBMCs, and if release levels could be used to assess severity and activity of chronic spontaneous urticaria (CSU). Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood from healthy donors and basophils isolated with MACS Basophil Isolation Kit to 97 to 99% purity. Cells were pulsed 1 hour with or without anti-IgE or with sera from CSU-patients/healthy controls and incubated for a total of 21 h before protein analysis of supernatants. MMP-9 and TNFa in supernatants were measured with commercial ELISAs (R & D), and histamine release determined with HR-test from RefLab ApS. Results: Stimulations with serum-pools demonstrated that CSU-serum, in contrast to healthy controls, was able to induce TNFa-release from isolated basophils. 10 sera from healthy controls and 22 sera from CSU-patients were tested for serum-induced histamine, TNFa and MMP-9 release. The CSU sera were grouped by reaction/no reaction in the autologous skin serum test (ASST), each group consisting of 11 sera. Nine of the 22 CSU-sera were found positive in the HR-test, 6 sera from ASST1 and 3 from ASSTpatients. Sera from ASST1 and ASST-patients were observed to induce highly significant MMP-9 and TNFa release from donor PBMCs when compared to sera from healthy controls (P , 0.001). Urticaria assessment score (UAS) did not appear to correlate with release levels for histamine, TNFa or MMP-9 in either group but in the ASST1 group, the ASST score appeared to be positive correlated to histamine and TNFa release and to a smaller degree to MMP-9 release. Conclusions: We have shown for the first time that serum from CSUpatients, in contrast to serum from healthy controls, can induce TNFa release from isolated basophils, as well as TNFa and MMP-9 from donor PBMCS. Release levels appeared to be positive correlated to ASST reaction in ASST1 patients but not to disease severity for CSU patients in general. Career of Medicine, Universidad Rafael Landivar, profesor of Immunology, Guatemala, Guatemala. Background: There are no previous studies published reporting allergen sensitizations in the population of most Central American countries, including Guatemala. There are many types of climates in different regions, with variable altitude, humidity, etc. The purpose of this study was to determine
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